Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Stifel analyst James Condulis downgraded Fulcrum Therapeutics Inc (NASDAQ:FULC) from Buy to Hold and cut the price target from $25 to $3. Fulcrum Therapeutics shares closed at $3.14 on Tuesday. See how other analysts view this stock.

Piper Sandler analyst Edward Tenthoff downgraded Fulcrum Therapeutics Inc (NASDAQ:FULC) from Overweight to Underweight and cut the price target from $23 to $3. Fulcrum Therapeutics shares closed at $3.14 on Tuesday. See how other analysts view this stock.

Truist Securities analyst Jonathan Bettenhausen downgraded Taylor Morrison Home Corp (NYSE:TMHC) from Buy to Hold and maintained a price target of $72.50. Taylor Morrison Home shares closed at $71.50 on Tuesday. See how other analysts view this stock.

Truist Securities analyst Gregory Renza downgraded Fulcrum Therapeutics Inc (NASDAQ:FULC) from Buy to Hold and cut the price target from $17 to $4. Fulcrum Therapeutics shares closed at $3.14 on Tuesday. See how other analysts view this stock.

Jefferies analyst Sheila Kahyaoglu downgraded StandardAero Inc (NYSE:SARO) from Buy to Hold and cut the price target from $34 to $30. StandardAero shares closed at $25.14 on Tuesday. See how other analysts view this stock.

Considering selling FULC stock? Here’s what analysts think: